EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC 4.0

Magnetic resonance imaging ‐guided transurethral ultrasound ablation for benign prostatic obstruction: 1‐year clinical outcomes of a phase II study

Antti Viitala iD, Mikael Anttinen iD, Pietari Mäkelä iD, Heikki Pärssinen, Pertti Nurminen, Teija Sainio iD, Jani Saunavaara iD, Pekka Taimen iD, Roberto Blanco Sequeiros iD, Peter J Boström iD

BJU International · 2025

DOI: 10.1111/bju.16795 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift BJU International, 2025. Verfasst von Antti Viitala und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic Radiology, University of Turku and Turku University Hospital, Turku, Finland. Hauptthemen laut MEDLINE: Prostatic Hyperplasia, Transurethral Resection of Prostate, Magnetic Resonance Imaging, Magnetic Resonance Imaging, Interventional. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: TYKS foundation, Finnish urological association, Finnish urological research foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate the safety and efficacy of magnetic resonance imaging (MRI)‐guided transurethral ultrasound ablation (TULSA) as a minimally invasive alternative for benign prostatic obstruction (BPO). Patients and Methods This prospective, single‐centre, early phase II study (NCT03350529) included 30 men with BPO scheduled for primary transurethral resection of the prostate. Assessments over 12 months included uroflowmetry, prostate‐specific antigen (PSA) levels, and validated questionnaires at baseline and 3‐month intervals. MRI was performed at baseline and at 3 and 12 months. Medication use and adverse events (AEs) were recorded and graded using the Clavien–Dindo classification.

Results

The median patient age at treatment was 67 years. During the 12‐month post‐TULSA follow‐up, prostate volume decreased from a median of 52 to 32 mL, and PSA levels from 3.1 to 1.5 μg/L. The maximum flow rate increased from 11.1 to 18.3 mL/s ( P < 0.001), and the average flow rate from 4.2 to 9.1 mL/s ( P < 0.001). Residual volume decreased from 71 to 40 mL, and voided volume increased from 211 to 301 mL. The International Prostate Symptom Score (IPSS) decreased from 17 to 4 ( P < 0.001), and IPSS quality of life score improved from 4 to 1 ( P < 0.001). The 26‐item Expanded Prostate Cancer Index Composite urinary irritative/obstructive scores improved from 66 to 94 ( P < 0.001), and urinary incontinence scores improved from 86 to 100 ( P = 0.008). Sexual function remained stable or improved. A total of 13 AEs were recorded, including 11 Grade II events (urinary tract infections/retentions) and one Grade IIIb event (epididymitis requiring drainage under general anaesthesia). All AEs resolved during follow‐up.

Conclusions

Transurethral ultrasound ablation appears to be a safe and effective experimental treatment for BPO, demonstrating clinically marked improvements in urinary function and quality of life at 12 months while preserving continence and sexual functions. However, it is not yet recommended by guidelines, and long‐term outcomes and validation in larger cohorts remain essential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic HyperplasiaTransurethral Resection of ProstateMagnetic Resonance ImagingMagnetic Resonance Imaging, InterventionalHumansMaleAgedProspective StudiesMiddle AgedTreatment OutcomeProstate-Specific AntigenProstateQuality of Life

Stichwörter der Autor:innen

LUTSTULSAablation therapybenign prostatic hyperplasiabenign prostatic obstructiontransurethral ultrasound ablation

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Department of Diagnostic Radiology, University of Turku and Turku University Hospital, Turku, Finland.
  • Department of Urology, University of Turku and Turku University Hospital, Turku, Finland.
  • Department of Medical Physics, University of Turku and Turku University Hospital, Turku, Finland.
  • Laboratory Division, Department of Pathology, Turku University Hospital, Turku, Finland.
  • Institute of Biomedicine and FICAN West Cancer Centre, University of Turku, Turku, Finland.

ORCID-Profile: Antti Viitala, Mikael Anttinen, Pietari Mäkelä, Teija Sainio, Jani Saunavaara, Pekka Taimen, Roberto Blanco Sequeiros, Peter J Boström

Förderung

  • TYKS foundation
  • Finnish urological association
  • Finnish urological research foundation
  • Emil Aaltosen Säätiö
  • Ida Montinin Säätiö
  • Turun Yliopisto
  • Finnish radiological society
  • Profound medical Inc

Zitieren

APA

Viitala, A., Anttinen, M., Mäkelä, P., Pärssinen, H., Nurminen, P., Sainio, T., Saunavaara, J., Taimen, P., Sequeiros, R. B., & Boström, P. J. (2025). Magnetic resonance imaging ‐guided transurethral ultrasound ablation for benign prostatic obstruction: 1‐year clinical outcomes of a phase II study. BJU International. https://doi.org/10.1111/bju.16795

Vancouver

Viitala A, Anttinen M, Mäkelä P, Pärssinen H, Nurminen P, Sainio T, et al. Magnetic resonance imaging ‐guided transurethral ultrasound ablation for benign prostatic obstruction: 1‐year clinical outcomes of a phase II study. BJU International. 2025. doi:10.1111/bju.16795

BibTeX
@article{Viitala2025,
  author = {Viitala, Antti and Anttinen, Mikael and Mäkelä, Pietari and Pärssinen, Heikki and Nurminen, Pertti and Sainio, Teija and Saunavaara, Jani and Taimen, Pekka and Sequeiros, Roberto Blanco and Boström, Peter J},
  title = {Magnetic resonance imaging ‐guided transurethral ultrasound ablation for benign prostatic obstruction: 1‐year clinical outcomes of a phase II study},
  journal = {BJU International},
  year = {2025},
  doi = {10.1111/bju.16795}
}
Kostenlos starten →